Drug Trial Radar · NCT07378098
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
254
Planned (sponsor's estimate)
Start
Feb 3, 2026
Primary completion
Mar 31, 2028
Study completion Sep 3, 2028
Sponsor
- Lead sponsor
- JW PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Jan 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus. The primary objectives of this trial were to answer the following questions: * Does KLH-2109 lower the amount of menstrual bleeding? * Does KLH-2109 reduce menstrual bleeding? * Is KLH-2109 safe for participants to use? Investigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective. Participants will be required to follow: * Take either KLH-2109 or the common treatment as a pill * Visit the clinic regularly for health checkups and safety tests * Keep track of their bleeding and any health changes during the study
Conditions
- Menorrhagia
- Uterine Fibroids
Interventions
KLH-2109+ Leurprorelin acetate PlaceboDrug
KLH-2109 200mg/day for 24 weeks(PO, QD) Leurprorelin acetate Placebo: Once every 4 weeks, subcutaneous injection
KLH-2109 Placebo + Leurprorelin acetateDrug
KLH-2109 Placebo: for 24 weeks(PO, QD) Leurprorelin acetate Placebo: 1.88mg or 3.75mg , Once every 4 weeks, subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with a total PBAC score < 10Time frame: Week 6 to the day before Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.